MASH Drug Development Summit on September 29-October 01, 2025 in Cambridge, United States

Driven by a surging pipeline, the MASH therapeutic landscape is radically transforming as more drugs reach clinical trials. While Madrigal's Rezdiffra marked a groundbreaking first approval, it also highlighted the vast scope for further, more comprehensive, patient-centered solutions. This is a pivotal moment to unlock unparalleled potential in conquering this widespread disease.

The 9th MASH Drug Development Summit is the essential forum for pharmaceutical giants and innovative biotechs dedicated to accelerating efficacious therapies for diverse patient populations. This year, we're diving deep into the game-changing potential of novel mechanisms of action, advanced biomarker integration, and strategic combination and sequential therapy regimens. Hear from titans such as Eli Lilly, AstraZeneca, Pfizer, and Takeda, alongside innovative biotechs such as Madrigal, Akero Therapeutics, 89 Bio, and more. Learn of the groundbreaking research and strategies focused on effective treatments through varied mechanisms and cell-targeting, accurate non-invasive biomarkers, patient-centered trial designs, and the profound potential of GLP-1s. The pressure is on to develop best-in-class treatments that transform patient lives.

Don't miss this pivotal opportunity to network with 60+ leading MASH scientists and drug development experts, forge crucial collaborations, and be part of the solution!

URLs:
Tickets: https://go.evvnt.com/3126388-2?pid=10008
Brochure: https://go.evvnt.com/3126388-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Pre-Conference Focus Day): USD 4197.00,

Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,

Academic and Not-for-Profit Pricing - 3 Day Pass (Conference + Pre-Conference Focus Day): USD 3597.00,

Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,

Solution Provider Pricing - 3 Day Pass (Conference + Pre-Conference Focus Day): USD 5097.00,

Solution Provider Pricing - 2 Day Pass (Conference Only): USD 3699.00

Speakers: Belle Van Rosmalen, Director, Medical Development, Incretin Outcomes, Eli Lilly, Cynthia Arbeeny, Chief Scientific Officer, Mitotherapeutix, Cynthia Lebaupin, Senior Scientist, Pfizer, Girish Rao, Executive Director, Clinical Design-Cardiometabolic Health, Clinical Design Delivery and Analytics, Eli Lilly, Hank Mansbach, Chief Medical Officer, 89 Bio, Jen-Chieh Chuang, Director, Translational Biomarker Lead, Liver diseases, Takeda Pharmaceuticals, Julio Gutierrez, Director, Medical, Altimmune, Kavita Juneja, Senior Director and Head of Metabolic Therapeutic Development, Corcept Therapeutics, Kevin Hart, Scientific Director, Pfizer, Kristin Fiorino, Director - Medical, AstraZeneca, Marie O'Farrell, Senior Vice President, Research and Development, Sagimet Biosciences, Oliver Yoa-Pu Hu, Scientific Board Member, Sinew Pharma, Patrice Mimche, Associate Professor, Indiana University, Rebecca Taub, Chief Executive Officer, Madrigal, Remi Laberge, Co-Founder and Chief Technology Officer, Arda Therapeutics, Reshma Shringapure, Vice President, Clinical Research Medical Affairs, Akero Therapeutics, Saheli Chowdhury, Postdoctoral Researcher, Columbia University, Sharon Jaycox, Director, Fatty Liver Disease, Global Liver Institute, Stanley Watowich, Founder and Chief Executive Officer, Ridgeline Therapeutics, Wen-Wei Tsai, Director, Sagimet Biosciences, Winston Dunn, Associate Professor, University of Kansas Medical Center, Zoltan Derdak, Medical Director, Early Clinical Development, Takeda Pharmaceuticals